Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals   Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA


do you wish to send a case report ?


CASE REPORTS in HAEMATOLOGY
(Paper co-edited with the European LeukemiaNet)
t(16;21)(q24;q22) in therapy-related acute myelogenous leukemia arising from myelodysplastic syndrome
 
Written2007-02Paola Dal Cin, Karim Ouahchi
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA
Clinics
Age and sex : 32 year(s) old male patient.
Previous History : preleukemia (RAEB diagnosed in 09-2006)
Hodgkin's lymphoma diagnosed in 2003
Organomegaly : no hepatomegaly ; no splenomegaly ; enlarged lymph nodes (History of Hodgkin's lymphoma involving right side neck lymph node); no central nervous system involvement
Blood
WBC : 0.29 x 109/L ; Hb : 10.7 g/dL ; platelets : 19 x 109/L;
Bone marrow : Megakaryocytes: none noted; Blasts: 65%; Promyelocytes: 1%; Myeloid Activity: 20%, occasional dysplastic forms; Erythroid Activity: 12%, occasional dysplastic forms; Lymphocytes: 2%
Cyto pathology classification
Cytology : M2 arising from previous myelodysplastic syndrome (RAEB-1)
Immunophenotype : Population of immature cells is positive for CD34 +, CD45 (dim), HLA-DR +, CD117 +, CD13 +, and CD33+ and negative for CD15-, monocytic, B and T lymphoid markers.
Pathology : Involvement by acute myelogenous leukemia (FAB-M2) with background dysmyelopoiesis.
Survival
Date of diagnosis: Hodgkin's lymphoma: (2003); myelodysplastic syndrome: (09-2006) karyotype was not performed; therapy-related AML: (01-11-2007) karyotype showing t(16;21)
Treatment : Chemotherapy and radiotherapy; chlorambucil, Vinblastine Procarbazine, Prednisone (MOPP) until June 2004; radiotherapy in 2004; ifosfamide, carboplatin and etoposide (ICE) in August 2005; autologous bone marrow transplant in August 2006, and conditioning regimen consisted of Cytoxan, BCNU and etoposide. Induction therapy in January 2007 (16-01-07) and preparation for second transplant.
Complete remission was obtained
Comments : bone marrow biopsy performed on 03-01-2007 showing no evidence of leukemia and 2% of blast. Karyotype performed on bone marrow aspirate was interpreted as 46, XY in 20 metaphases.
Relapse : -
Status : Alive 03-2007
Karyotype
Sample : Bone marrow aspirate ; culture time : 24 h ; banding : GTG
Results : 49,XY,+Y,+3,+8,t(16;21)(q24;q22)[18]/46,XY[2]
Other molecular cytogenetics technics : FISH evaluation for AML1 rearrangement was performed on abnormal metaphases with the LSI TEL/AML1 ES Dual Color Translocation Probe (Abbott Molecular/Vysis, Inc.).
Other molecular cytogenetics results : Ish der(16)(dimAML1+), der(21)(dimAML1+)[5/5] (see Fig. 2).
Partial GTG-banding karyotype showing t(16;21)(q24;q22)(a) and numerical anomalies.
Partial FISH analysis showing the AML1 hybridization signals on the derivative chromosomes 16 and 21 and on the normal chromosome 21(b).
Comments
The t(16;21) was reported mostly in t-MDS/t-AML, and classified as M2 in a majority of cases. Two cases including this current report were observed after treatment for Hodgkin lymphoma.
Trisomy 8 is a frequent secondary abnormality associated with t(16;21), however in this current case we also report the presence of an additional chromosome Y and trisomy 3.
Internal links
Atlas Cardt(16;21)(q24;q22)
Case ReportA new case of t(16;21)(q24;q22) in a secondary AML-M2 following breast cancer therapy
Case ReportA case of trisomy 8 and loss of the Y-chromosome as secondary aberrations in a ten year old boy with de novo AML FAB M2 and t(16;21)(q24;q22)
Bibliography
t(16;21)(q24;q22).
Pérot C .
Atlas Genet Cytogenet Oncol Haematol 1998; 2 (3): 335-338. http://AtlasGeneticsOncology.org/Anomalies/t1621ID1123.html
 
A pediatric case of secondary leukemia associated with t(16;21)(q24;q22) exhibiting the chimeric AML1-MTG16 gene.
Kondoh K, Nakata Y, Furuta T, Hosoda F, Gamou T, Kurosawa Y, Kinoshita A, Ohki M, Tomita Y, Mori T.
Leuk Lymphoma. 2002; 43: 415-420.
PMID 11999578
 
t(16;21)(q24;q22).
Huret JL.
Atlas Genet Cytogenet Oncol Haematol 2003; 7 (4): 576-578. http://AtlasGeneticsOncology.org/Anomalies/t1621ID1123.html
 
Abnormalities of the long arm of chromosome 21 in 107 patients with hematopoietic disorders: a collaborative retrospective study of the Groupe Francais de Cytogenetique Hematologique.
Jeandidier E, Dastugue N, Mugneret F, Lafage-Pochitaloff M, Mozziconacci MJ, Herens C, Michaux L, Verellen-Dumoulin C, Talmant P, Cornillet-Lefebvre P, Luquet I, Charrin C, Barin C, Collonge-Rame MA, Perot C, Van den Akker J, Gregoire MJ, Jonveaux P, Baranger L, Eclache-Saudreau V, Pages MP, Cabrol C, Terre C, Berger R; Groupe Francais de Cytogenetique Hematologique (GFCH).
Cancer Genet Cytogenet. 2006; 166: 1-11.
PMID 16616106
 

Citation

This paper should be referenced as such :
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Reports/1621DalCinID100022.html

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Oct 27 11:27:37 CEST 2017


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals   Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.